基本信息
浏览量:398
职业迁徙
个人简介
RESEARCH FOCUS:
The study of signaling pathways in hematological malignancies and in particular multiple myeloma with the goal of discovering new molecular targets for therapeutic applications. I have been investigating the mechanisms by which arsenic trioxide induces death in multiple myeloma in vitro. These studies have focused on the intracellular mechanisms of arsenicmediated reactive oxygen species generation in the induction of apoptosis, evaluation of the role of the glutathione redox pathway and related enzymes in chemoresistance and the study of glutathione depleting agents in vitro. This research indicated a central role for intracellular glutathione (GSH) in protecting against arsenicinduced death. We have subsequently found that ascorbic acid, as a prooxidant, can deplete intracellular GSH in myeloma cells, resulting in increased arsenic trioxide efficacy. These studies were recently published in BLOOD. These studies were the basis of an NCIsponsored phase I/II clinical trial using arsenic trioxide+ ascorbic acid n refractory/relapsed multiple myeloma. My studies have been extended to clinical samples from this trial. The results of the phase I clinical trial were published in the 2002 December issue of Clinical Cancer Research.
The study of signaling pathways in hematological malignancies and in particular multiple myeloma with the goal of discovering new molecular targets for therapeutic applications. I have been investigating the mechanisms by which arsenic trioxide induces death in multiple myeloma in vitro. These studies have focused on the intracellular mechanisms of arsenicmediated reactive oxygen species generation in the induction of apoptosis, evaluation of the role of the glutathione redox pathway and related enzymes in chemoresistance and the study of glutathione depleting agents in vitro. This research indicated a central role for intracellular glutathione (GSH) in protecting against arsenicinduced death. We have subsequently found that ascorbic acid, as a prooxidant, can deplete intracellular GSH in myeloma cells, resulting in increased arsenic trioxide efficacy. These studies were recently published in BLOOD. These studies were the basis of an NCIsponsored phase I/II clinical trial using arsenic trioxide+ ascorbic acid n refractory/relapsed multiple myeloma. My studies have been extended to clinical samples from this trial. The results of the phase I clinical trial were published in the 2002 December issue of Clinical Cancer Research.
研究兴趣
论文共 661 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Leukemia & lymphomano. 3 (2024): 403-406
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 11 (2024): 1207-1210
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICAno. 2 (2024): 305-319
Karthik Ramasamy,Nizar J Bahlis,Shaji K Kumar,Arun Kumar, Holly Cranmer,Bingxia Wang, Jonathan Dabora,Richard Labotka,Paul G Richardson,Philippe Moreau
Haematologica (2024)
Paola Neri,Benjamin G. Barwick, David Jung, Jonathan C. Patton,Ranjan Maity,Ines Tagoug,Caleb K. Stein,Remi Tilmont,Noemie Leblay,Sungwoo Ahn,Holly Lee,Seth J. Welsh,
BLOOD CANCER DISCOVERYno. 1 (2024): 56-73
BLOOD CANCER DISCOVERYno. 1 (2024): 34-55
BLOOD CANCER JOURNALno. 1 (2024)
Advances in therapyno. 4 (2024): 1576-1593
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn